JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
A8307 Crenolanib (CP-868596)
1 Citation

Target: FLT3|PDGFR

Summary: PDGFR-β inhibitor,potent and selective

≥22.2 mg/mL
A8476 MK-2461

Target: FLT3|PDGFR|MET|Ron

Summary: C-Met (WT/mutants) inhibitor

≥24.8 mg/mL
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8245 Sorafenib Tosylate
1 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥31.85 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A8255 Sunitinib malate
2 Citation

Target: VEGFR

Summary: VEGFR/PDGFRβ/ KIT/ FLT3/RET/CSF-1R inhibitor

≥26.65 mg/mL
A2942 Masitinib (AB1010)

Target: PDGFR|c-Kit|Lyn

Summary: Tyrosine kinase inhibitor, potent and selective

≥24.95 mg/mL
A2477 Tyrphostin AG 1296
1 Citation

Target: PDGFR

Summary: PDGFR inhibitor,selective and ATP-competitive